Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt ...

SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a ...

Illumina's technology is extremely well-established, and serves as the backbone for most large-scale genome sequencing projects currently underway (including the majority of the samples sequenced ...

For a one-time fee of $985, you can get your genome analyzed on the Web. DeCODE Genetics, based in Reykjavik, Iceland, today is launching a new service that that it says will provide a detailed ...

Illumina, Inc. has unveiled a service program to provide high-quality personal genome sequencing for consumers. This is the first service to offer complete coverage of the human genome sequence for ...

23andMe Holding Co. will be sold to TTAM Research Institute, a genetics-led healthcare company based in California and led by 23andMe co-founder and former CEO Anne Wojcicki.

Anne Wojcicki's nonprofit will acquire substantially all of 23andMe's assets for $305 million, the company announced Friday.

Under the proposed agreement with Regeneron, the Tarrytown, New York, drugmaker will acquire 23andMe's assets, including its personal genome service and total health and research services.